Form 4: Director Mark McClellan Receives JNJ Deferred Share Units
Statement of Changes in Beneficial Ownership
Johnson & Johnson Director Mark B. McClellan was granted 975 deferred share units as part of the company's director compensation plan.
Summary
- Director Mark B. McClellan acquired 975 Deferred Share Units (DSUs) on April 23, 2026.
- The DSUs were granted under the Issuer's Amended and Restated Deferred Fee Plan for Directors.
- These units are to be settled in cash upon the termination of the director's service.
- Following this transaction, the director holds a total of 21,278.593 units, which includes accrued dividend equivalent rights.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company operations or financial strategy.
Positives
- The transaction reflects standard director compensation practices aligned with long-term equity retention.
- The increase in holdings demonstrates continued alignment between the director and shareholder interests.
Negatives
- None identified.
Risks
- The value of the deferred share units is tied to the future performance of Johnson & Johnson common stock.
Future Outlook
The DSUs will be settled in cash upon the termination of the director's service, with the value determined by the fair market value of JNJ common stock at that time.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation, consistent with standard corporate governance practices for large-cap pharmaceutical companies.
Comparison to Industry Standards
- The use of deferred share units for director compensation is a standard practice among S&P 500 companies to ensure board members maintain a long-term stake in company performance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Mark McClellan authorized several JNJ and Skadden Arps personnel to file SEC documents on his behalf. | 2026-01-03 | Administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Minimal impact; the transaction represents standard director compensation.
Next Steps
- No further action required; the director will continue to hold these units until the termination of their directorship.
Key Dates
| Date | Description |
|---|---|
| 2026-01-03 | Date of Power of Attorney execution. |
| 2026-04-23 | Date of the reported transaction (grant of DSUs). |
| 2026-04-27 | Date of filing. |
Keywords
Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.